董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Peters | 男 | Director | 60 | 9.07万美元 | 未持股 | 2023-07-11 |
| Michael Grissinger | 男 | Director | 69 | 6.83万美元 | 未持股 | 2023-07-11 |
| Bernd R. Seizinger | 男 | Director | 66 | 8.68万美元 | 未持股 | 2023-07-11 |
| Marc Duey | 男 | Director | 67 | 6.25万美元 | 未持股 | 2023-07-11 |
| Rifat Pamukcu | 男 | Director | 65 | 6.49万美元 | 未持股 | 2023-07-11 |
| Gabriela Gruia | 女 | Director | 67 | 未披露 | 未持股 | 2023-07-11 |
| Oren Gilad | 男 | Chief Executive Officer and President and Director | 55 | 75.32万美元 | 未持股 | 2023-07-11 |
| Christian S. Schade | 男 | Chairman | 62 | 145.29万美元 | 未持股 | 2023-07-11 |
| John B. Henneman, III | 男 | Director | 61 | 11.95万美元 | 未持股 | 2023-07-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Oren Gilad | 男 | Chief Executive Officer and President and Director | 55 | 75.32万美元 | 未持股 | 2023-07-11 |
| John P. Hamill | 男 | Senior Vice President, Chief Financial Officer and Secretary | 59 | 未披露 | 未持股 | 2023-07-11 |
董事简历
中英对照 | 中文 | 英文- Richard Peters
-
Richard Peters，医学博士，博士，自2017年2月起担任我们的总裁兼首席执行官兼董事会成员。在加入我们之前，彼得斯博士自2008年以来一直在赛诺菲健赞（Sanofi Genzyme）担任多个职位，赛诺菲健赞是一家全球制药公司，包括自2015年1月以来担任全球罕见病业务部门高级副总裁，主管Vice President、战略发展官，2014年5月至2014年12月任美国罕见病部门Vice President，2011年至2014年5月任全球肿瘤科医疗干事，2008年至2011年任全球和美国医疗事务、血液学和移植主管Vice President。任职Sanofi Genzyme公司之前，彼得斯博士曾在OnyxPharmaceuticals，Inc.和安进公司这两家制药公司担任医疗事务职务，并是梦百合信息技术公司MedNav，Inc.的联合创始人兼首席执行官。Peters博士还曾在Harvard Medical School/Massachusetts General Hospital担任教员。Peters博士拥有南卡罗来纳医科大学（Medical University of South Carolina）的药理学硕士学位和博士学位，以及查尔斯顿学院（College of Charleston）的工商管理硕士学位。
Richard Peters, M.D., Ph.D. has served as President and Chief Executive Officer and a member of board of directors of Merrimack Pharmaceuticals, Inc. since February 2017. Prior to joining of Merrimack Pharmaceuticals, Inc. , Dr. Peters served in various capacities at Sanofi Genzyme, a global pharmaceutical company, since 2008 including as Senior Vice President, Head of Global Rare Diseases Business Unit since January 2015 Vice President, Strategy Development Officer, U.S. Rare Disease Unit from May 2014 to December 2014 Vice President, Division Medical Officer, Global Oncology Division from 2011 to May 2014 and Vice President, Head of Global and U.S. Medical Affairs, Hematology and Transplant from 2008 to 2011. Prior to Sanofi Genzyme, Dr. Peters held medical affairs roles at Onyx Pharmaceuticals, Inc. and Amgen Inc., both pharmaceutical companies, and was a co-founder and Chief Executive Officer of Mednav, Inc., a healthcare information technology company. Dr. Peters has also served on the faculty at Harvard Medical School/Massachusetts General Hospital. Dr. Peters holds an M.D. and a Ph.D. in pharmacology from the Medical University of South Carolina and a B.S. from the College of Charleston. - Richard Peters，医学博士，博士，自2017年2月起担任我们的总裁兼首席执行官兼董事会成员。在加入我们之前，彼得斯博士自2008年以来一直在赛诺菲健赞（Sanofi Genzyme）担任多个职位，赛诺菲健赞是一家全球制药公司，包括自2015年1月以来担任全球罕见病业务部门高级副总裁，主管Vice President、战略发展官，2014年5月至2014年12月任美国罕见病部门Vice President，2011年至2014年5月任全球肿瘤科医疗干事，2008年至2011年任全球和美国医疗事务、血液学和移植主管Vice President。任职Sanofi Genzyme公司之前，彼得斯博士曾在OnyxPharmaceuticals，Inc.和安进公司这两家制药公司担任医疗事务职务，并是梦百合信息技术公司MedNav，Inc.的联合创始人兼首席执行官。Peters博士还曾在Harvard Medical School/Massachusetts General Hospital担任教员。Peters博士拥有南卡罗来纳医科大学（Medical University of South Carolina）的药理学硕士学位和博士学位，以及查尔斯顿学院（College of Charleston）的工商管理硕士学位。
- Richard Peters, M.D., Ph.D. has served as President and Chief Executive Officer and a member of board of directors of Merrimack Pharmaceuticals, Inc. since February 2017. Prior to joining of Merrimack Pharmaceuticals, Inc. , Dr. Peters served in various capacities at Sanofi Genzyme, a global pharmaceutical company, since 2008 including as Senior Vice President, Head of Global Rare Diseases Business Unit since January 2015 Vice President, Strategy Development Officer, U.S. Rare Disease Unit from May 2014 to December 2014 Vice President, Division Medical Officer, Global Oncology Division from 2011 to May 2014 and Vice President, Head of Global and U.S. Medical Affairs, Hematology and Transplant from 2008 to 2011. Prior to Sanofi Genzyme, Dr. Peters held medical affairs roles at Onyx Pharmaceuticals, Inc. and Amgen Inc., both pharmaceutical companies, and was a co-founder and Chief Executive Officer of Mednav, Inc., a healthcare information technology company. Dr. Peters has also served on the faculty at Harvard Medical School/Massachusetts General Hospital. Dr. Peters holds an M.D. and a Ph.D. in pharmacology from the Medical University of South Carolina and a B.S. from the College of Charleston.
- Michael Grissinger
-
Michael Grissinger自2018年11月以来一直担任我们的董事会成员。Grissinger先生目前是制药业务的独立董事和顾问。在1996年1月开始了22年的职业生涯后，他于2018年4月从强生公司退休，2016年4月至2018年4月，他Vice President担任过Vice President并购业务、资产剥离和免疫学业务发展等多个职位，2014年1月至2016年3月为Corporate Development Pharmaceuticals，2002年1月至2013年12月为Vice President Pharmaceutical Business Development and Licensing。在强生公司，他领导的交易和团队涉及广泛的交易类型、地域和治疗性疾病领域。Grissinger先生目前在AkariTherapeutics，Plc和Atrin Pharmaceuticals，Inc.的董事会任职。Grissinger先生拥有Juniata College的化学学士学位和Temple University-Fox School of Business的工商管理硕士学位。
Michael Grissinger has served as a member of board of directors of Adicet Bio, Inc. since November 2018. Mr. Grissinger is currently an independent director and advisor in the pharmaceuticals business. He retired from Johnson & Johnson, Inc. in April 2018 after a 22-year career beginning in January 1996 holding various positions such as Vice President M&A Operations, Divestitures, and Immunology Business Development from April 2016 to April 2018 Vice President, Corporate Development Pharmaceuticals from January 2014 to March 2016 and Vice President Pharmaceutical Business Development and Licensing from January 2002 to December 2013. At Johnson & Johnson, he led transactions and teams across a broad span of deal-types, geographies, and therapeutic disease areas. Mr. Grissinger currently serves on the boards of Akari Therapeutics, plc and Atrin Pharmaceuticals, Inc. Mr. Grissinger holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University-Fox School of Business. - Michael Grissinger自2018年11月以来一直担任我们的董事会成员。Grissinger先生目前是制药业务的独立董事和顾问。在1996年1月开始了22年的职业生涯后，他于2018年4月从强生公司退休，2016年4月至2018年4月，他Vice President担任过Vice President并购业务、资产剥离和免疫学业务发展等多个职位，2014年1月至2016年3月为Corporate Development Pharmaceuticals，2002年1月至2013年12月为Vice President Pharmaceutical Business Development and Licensing。在强生公司，他领导的交易和团队涉及广泛的交易类型、地域和治疗性疾病领域。Grissinger先生目前在AkariTherapeutics，Plc和Atrin Pharmaceuticals，Inc.的董事会任职。Grissinger先生拥有Juniata College的化学学士学位和Temple University-Fox School of Business的工商管理硕士学位。
- Michael Grissinger has served as a member of board of directors of Adicet Bio, Inc. since November 2018. Mr. Grissinger is currently an independent director and advisor in the pharmaceuticals business. He retired from Johnson & Johnson, Inc. in April 2018 after a 22-year career beginning in January 1996 holding various positions such as Vice President M&A Operations, Divestitures, and Immunology Business Development from April 2016 to April 2018 Vice President, Corporate Development Pharmaceuticals from January 2014 to March 2016 and Vice President Pharmaceutical Business Development and Licensing from January 2002 to December 2013. At Johnson & Johnson, he led transactions and teams across a broad span of deal-types, geographies, and therapeutic disease areas. Mr. Grissinger currently serves on the boards of Akari Therapeutics, plc and Atrin Pharmaceuticals, Inc. Mr. Grissinger holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University-Fox School of Business.
- Bernd R. Seizinger
-
Bernd R. Seizinger，自2015年起担任Aprea Therapeutics, Inc.董事会成员。他是多家公司的董事会成员，包括Opsona Dublin, Ireland, Agennix AG （Princeton, NJ；休斯顿，德克萨斯州；德国慕尼黑）和TriMod有限公司（爱尔兰都柏林）。他是Opsona Ltd.的主席。以及Trimod有限公司的代理主席。从1998年到2009年，他担任GPC Biotech（与Agennix AG合并之前）的总裁兼首席执行官。在他的公司任命之前，他在麻省总医院和哈佛医学院。
Bernd R. Seizinger,has served as a member of board of directors of Aprea Therapeutics, Inc. since 2015. Dr. Seizinger is a board member in a number of public and private biotech companies in the United States, Europe, and Canada, including Aptose Biosciences Inc., Oxford BioTherapeutics Ltd., Nykode Therapeutics ASA, BioInvent International AB, Oncolytics Biotech Inc. and CryptoMedix Inc. Previously, Dr. Seizinger was President and Chief Executive Officer of GPC Biotech, VP Oncology Drug Discovery at Bristol-Myers Squibb Company, and Executive VP and Chief Scientific Officer at Genome Therapeutics. Prior to his corporate appointments, he held senior faculty positions at Massachusetts Harvard Medical School, Massachusetts General Hospital and Princeton University. - Bernd R. Seizinger，自2015年起担任Aprea Therapeutics, Inc.董事会成员。他是多家公司的董事会成员，包括Opsona Dublin, Ireland, Agennix AG （Princeton, NJ；休斯顿，德克萨斯州；德国慕尼黑）和TriMod有限公司（爱尔兰都柏林）。他是Opsona Ltd.的主席。以及Trimod有限公司的代理主席。从1998年到2009年，他担任GPC Biotech（与Agennix AG合并之前）的总裁兼首席执行官。在他的公司任命之前，他在麻省总医院和哈佛医学院。
- Bernd R. Seizinger,has served as a member of board of directors of Aprea Therapeutics, Inc. since 2015. Dr. Seizinger is a board member in a number of public and private biotech companies in the United States, Europe, and Canada, including Aptose Biosciences Inc., Oxford BioTherapeutics Ltd., Nykode Therapeutics ASA, BioInvent International AB, Oncolytics Biotech Inc. and CryptoMedix Inc. Previously, Dr. Seizinger was President and Chief Executive Officer of GPC Biotech, VP Oncology Drug Discovery at Bristol-Myers Squibb Company, and Executive VP and Chief Scientific Officer at Genome Therapeutics. Prior to his corporate appointments, he held senior faculty positions at Massachusetts Harvard Medical School, Massachusetts General Hospital and Princeton University.
- Marc Duey
-
Marc Duey自2022年5月起担任Aprea Therapeutics公司董事会成员，当时他被任命参与Aprea Therapeutics公司收购Atrin Pharmaceuticals公司的交易。Duey先生在制药和生物技术行业拥有40多年的经验，并带来了大量的商业业务和产品发布经验。自2012年以来，他一直担任Duce Management，LLC的管理合伙人。Duce Management，LLC是一家家族理财室基金，专注于生物技术和数字健康的融合，通过早期阶段的承诺，向拥有知识产权和平台技术的新兴公司提供帮助，这些技术最终会让寻求潜在癌症治疗方法的专业制药公司感兴趣。杜伊先生于1993年至2019年担任ProMetrics，Inc.的创始人、总裁和首席执行官，该公司是专业制药行业领先的销售和患者级数据聚合器和服务提供商，已有20多年的历史。ProMetrics现在是ConcertAI的患者解决方案部门，ConcertAI是一家领先的真实世界数据公司，也是最大、最雄心勃勃、最具活力的肿瘤公司的基于AI的预测分析合作伙伴。杜伊创立了ProMetrics，为营销和销售团队提供战略和战术决策支持。在他的指导下，该公司帮助推出了数十种生物制药产品，为150多个客户提供服务，并管理了数千个项目。7家客户生物技术公司已被7家大型肿瘤公司收购，交易总额超过1500亿美元。在创立ProMetrics之前，Duey先生是DuWest Research的创始人和总裁。DuWest Research是一家国际管理咨询公司，在三大洲设有办事处，专门服务于诊断和生物技术公司的需求。杜伊是众多行业协会的成员，也是多家科技公司的董事会成员。他是西切斯特大学商学院和医药产品研究所开发项目（PPD）的兼职教授。他是费城国际之家董事会成员，也是Wistar研究所领导委员会成员。他是美国临床肿瘤学会（ASCO）、美国癌症研究协会（AACR）、美国药物科学协会（AAPS）和授权执行协会（LES）的活跃成员。Duey先生拥有渥太华大学的理学学士和理学硕士学位，以及加拿大伦敦西部大学艾维商学院的工商管理硕士学位。
Marc Duey,has been a member of Board of Aprea Therapeutics, Inc. since May 2022, when he was appointed in connection with Aprea Therapeutics, Inc. acquisition of Atrin Pharmaceuticals, Inc. Since 2012, he has served as a Managing Partner at Duce Management, LLC, a family office fund that focuses on biotech and digital health convergence via early-stage commitments to emerging firms with intellectual property and platform technology of eventual interest to specialty pharmaceutical manufacturers seeking potential therapies for cancer. Mr. Duey was the Founder, President, and CEO of ProMetrics, Inc., from 1993 to 2019, a leading sales and patient-level data aggregator and service provider to the specialty pharmaceutical industry for over two decades. ProMetrics is now the Patient Solutions Division of ConcertAI, a leading real-world data, and AI-based predictive analytics partner to the largest, most ambitious, and dynamic oncology firms. Mr. Duey founded ProMetrics to provide marketing and sales teams with strategic and tactical decision support. Under his direction, the firm helped launch dozens of biopharma products, serviced over 150 clients, and managed thousands of projects. Seven client biotech firms have been acquired by seven large oncology companies, also clients, for a total transaction value of over $150 billion. Prior to founding ProMetrics, Mr. Duey was the founder and President of DuWest Research, an international management consulting firm, with offices on three continents, which specialized in serving the needs of diagnostic and biotechnology firms. Mr. Duey is a member of numerous trade and industry associations and sits on the Board of Directors of several technology companies. He is an adjunct professor at West Chester University in both the Business School and the Pharmaceutical Product Development program (PPD). He serves on the Board of Trustees of International House Philadelphia and is a member of the Leadership Council of the Wistar Institute. He is an active member of the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), the American Association of Pharmaceutical Science (AAPS), and the Licensing Executive Society (LES). Mr. Duey holds a B.S. and an M.S. degree in science from the University of Ottawa, and an M.B.A. from the Ivey Business School at Western University, London, Canada. - Marc Duey自2022年5月起担任Aprea Therapeutics公司董事会成员，当时他被任命参与Aprea Therapeutics公司收购Atrin Pharmaceuticals公司的交易。Duey先生在制药和生物技术行业拥有40多年的经验，并带来了大量的商业业务和产品发布经验。自2012年以来，他一直担任Duce Management，LLC的管理合伙人。Duce Management，LLC是一家家族理财室基金，专注于生物技术和数字健康的融合，通过早期阶段的承诺，向拥有知识产权和平台技术的新兴公司提供帮助，这些技术最终会让寻求潜在癌症治疗方法的专业制药公司感兴趣。杜伊先生于1993年至2019年担任ProMetrics，Inc.的创始人、总裁和首席执行官，该公司是专业制药行业领先的销售和患者级数据聚合器和服务提供商，已有20多年的历史。ProMetrics现在是ConcertAI的患者解决方案部门，ConcertAI是一家领先的真实世界数据公司，也是最大、最雄心勃勃、最具活力的肿瘤公司的基于AI的预测分析合作伙伴。杜伊创立了ProMetrics，为营销和销售团队提供战略和战术决策支持。在他的指导下，该公司帮助推出了数十种生物制药产品，为150多个客户提供服务，并管理了数千个项目。7家客户生物技术公司已被7家大型肿瘤公司收购，交易总额超过1500亿美元。在创立ProMetrics之前，Duey先生是DuWest Research的创始人和总裁。DuWest Research是一家国际管理咨询公司，在三大洲设有办事处，专门服务于诊断和生物技术公司的需求。杜伊是众多行业协会的成员，也是多家科技公司的董事会成员。他是西切斯特大学商学院和医药产品研究所开发项目（PPD）的兼职教授。他是费城国际之家董事会成员，也是Wistar研究所领导委员会成员。他是美国临床肿瘤学会（ASCO）、美国癌症研究协会（AACR）、美国药物科学协会（AAPS）和授权执行协会（LES）的活跃成员。Duey先生拥有渥太华大学的理学学士和理学硕士学位，以及加拿大伦敦西部大学艾维商学院的工商管理硕士学位。
- Marc Duey,has been a member of Board of Aprea Therapeutics, Inc. since May 2022, when he was appointed in connection with Aprea Therapeutics, Inc. acquisition of Atrin Pharmaceuticals, Inc. Since 2012, he has served as a Managing Partner at Duce Management, LLC, a family office fund that focuses on biotech and digital health convergence via early-stage commitments to emerging firms with intellectual property and platform technology of eventual interest to specialty pharmaceutical manufacturers seeking potential therapies for cancer. Mr. Duey was the Founder, President, and CEO of ProMetrics, Inc., from 1993 to 2019, a leading sales and patient-level data aggregator and service provider to the specialty pharmaceutical industry for over two decades. ProMetrics is now the Patient Solutions Division of ConcertAI, a leading real-world data, and AI-based predictive analytics partner to the largest, most ambitious, and dynamic oncology firms. Mr. Duey founded ProMetrics to provide marketing and sales teams with strategic and tactical decision support. Under his direction, the firm helped launch dozens of biopharma products, serviced over 150 clients, and managed thousands of projects. Seven client biotech firms have been acquired by seven large oncology companies, also clients, for a total transaction value of over $150 billion. Prior to founding ProMetrics, Mr. Duey was the founder and President of DuWest Research, an international management consulting firm, with offices on three continents, which specialized in serving the needs of diagnostic and biotechnology firms. Mr. Duey is a member of numerous trade and industry associations and sits on the Board of Directors of several technology companies. He is an adjunct professor at West Chester University in both the Business School and the Pharmaceutical Product Development program (PPD). He serves on the Board of Trustees of International House Philadelphia and is a member of the Leadership Council of the Wistar Institute. He is an active member of the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), the American Association of Pharmaceutical Science (AAPS), and the Licensing Executive Society (LES). Mr. Duey holds a B.S. and an M.S. degree in science from the University of Ottawa, and an M.B.A. from the Ivey Business School at Western University, London, Canada.
- Rifat Pamukcu
-
Rifat Pamukcu，自2022年5月因Aprea Therapeutics公司收购Atrin Pharmaceuticals公司而被任命为Aprea Therapeutics公司董事会成员。Pamukcu在制药和药物开发方面拥有丰富的经验，尤其专注于肿瘤学。他曾是Cell Pathways的联合创始人、董事和CSO，Cell Pathways是一家上市制药公司，专注于癌症和癌症预防，2003年被OSI Pharmaceuticals收购。在Cell Pathways，他指导基础科学、临床前药物开发、临床研究、监管计划以及化学放大和制造的各个方面，并筹集了超过1.4亿美元的投资资金。他自2016年起担任RXMP Therapeutics，Inc.的董事、总裁兼首席执行官，该公司是一家私营制药公司，正在研发新型全身给药止血剂，旨在阻止或防止过度出血。Pamukcu博士自2005年起担任Midway Pharmaceuticals DBA MidwayBiome的董事、总裁和首席执行官。MidwayBiome是一家私营制药公司，正在开发影响胃肠道和微生物组相互作用的非抗生素方法，以帮助治疗胃肠道和全身疾病。自2016年以来，他一直是Corami LLC的管理合伙人，该公司是一家处于早期阶段的治疗公司，致力于开发将缓释疗法直接输送到心脏外表面的药物设备组合。Pamukcu博士自2019年起担任Syantra，Inc.（一家乳腺癌诊断公司）董事会成员，自2021年起担任Sirpant Immunotherapeutics，Inc.（一家血液系统恶性肿瘤免疫治疗公司）董事会成员，自2018年起担任Virion Therapeutics LLC（一家肝炎治疗疫苗公司）董事会成员。他是国家前列腺癌联盟咨询委员会、美国胃肠病学协会胃肠道肿瘤研究小组、胃肠病学研究小组执行指导委员会和遗传性结肠癌协会科学咨询委员会的成员。自1985年以来，Pamukcu博士在胃肠病学、癌症、癌症化学预防和信号传导系统领域撰写或合著了110多篇期刊文章、书籍章节和摘要。他是150多项已发布或正在申请的专利的发明人，这些专利涉及药物发现和开发用于癌症预防和治疗、炎症性肠病、骨质疏松症以及预防和治疗出血的药物。Pamukcu博士拥有约翰霍普金斯大学生物学学士学位和威斯康星大学医学院医学博士学位。他在Rush Presbyterian St. Luke's Medical Center完成了内科住院治疗，并在芝加哥大学完成了胃肠病学和肝病学研究金。在加入Cell Pathways公司之前，他是辛辛那提大学消化疾病科的助理教授。
Rifat Pamukcu,has been a member of Board of Aprea Therapeutics, Inc. since May 2022, when he was appointed in connection with Aprea Therapeutics, Inc. acquisition of Atrin Pharmaceuticals, Inc.Dr. Pamukcu has extensive experience in pharmaceuticals and drug development, with a particular focus on oncology.He was a co-founder, director and CSO of Cell Pathways, a publicly traded pharmaceutical company focused on cancer and cancer prevention that was acquired by OSI Pharmaceuticals in 2003). At Cell Pathways he directed the basic science, preclinical drug development, clinical research, regulatory programs, and various aspects of chemical scale-up and manufacturing and raised over $140 million of investment capital. He is currently director, President and CEO of RXMP Therapeutics, Inc. since 2016, a private pharmaceutical company that is developing novel systemically delivered hemostatic agents that are designed to arrest or prevent excessive bleeding. Dr. Pamukcu has served as director, President and CEO of Midway Pharmaceuticals DBA MidwayBiome since 2005, a private pharmaceutical company that is developing nonantibiotic approaches to affect GI tract and microbiome interactions to aid in gastrointestinal and systemic disorders. He has been a Managing Partner of Corami LLC since 2016, an early-stage therapeutics company developing drug-device combinations that deliver sustained release therapeutics directly to the external surface of the heart. Dr. Pamukcu serves on the Board of Directors of Syantra, Inc. since 2019 (a breast cancer diagnostics company), Sirpant Immunotherapeutics, Inc. since 2021 (a hematological malignancy immunotherapeutics company), and Virion Therapeutics LLC since 2018 (a hepatitis therapeutic vaccine company). He has been a member of the Advisory Council to the National Prostate Cancer Coalition, the GI Oncology Task Force of the American Gastroenterological Association, Executive Steering Committee of the Gastroenterology Research Group and Scientific Advisory Board of the Hereditary Colon Cancer Association. Since 1985, Dr. Pamukcu has authored or co-authored over 110 journal articles, book chapters and abstracts in the fields of gastroenterology, cancer, cancer chemoprevention and signal transduction systems. He is an inventor on over 150 issued or pending patents in the areas of drug discovery and development of agents for cancer prevention and therapeutics,inflammatory bowel disease, osteoporosis and the prevention and treatment of hemorrhage. Dr. Pamukcu holds a B.A. in Biology from John Hopkins University and an M.D. from the University of Wisconsin School of Medicine. He completed his Internal Medicine Residency at Rush Presbyterian St. Luke's Medical Center and his Fellowship in Gastroenterology and Hepatology at the University of Chicago. He was an Assistant Professor in the Division of Digestive Diseases at the University of Cincinnati prior to his joining Cell Pathways, Inc. - Rifat Pamukcu，自2022年5月因Aprea Therapeutics公司收购Atrin Pharmaceuticals公司而被任命为Aprea Therapeutics公司董事会成员。Pamukcu在制药和药物开发方面拥有丰富的经验，尤其专注于肿瘤学。他曾是Cell Pathways的联合创始人、董事和CSO，Cell Pathways是一家上市制药公司，专注于癌症和癌症预防，2003年被OSI Pharmaceuticals收购。在Cell Pathways，他指导基础科学、临床前药物开发、临床研究、监管计划以及化学放大和制造的各个方面，并筹集了超过1.4亿美元的投资资金。他自2016年起担任RXMP Therapeutics，Inc.的董事、总裁兼首席执行官，该公司是一家私营制药公司，正在研发新型全身给药止血剂，旨在阻止或防止过度出血。Pamukcu博士自2005年起担任Midway Pharmaceuticals DBA MidwayBiome的董事、总裁和首席执行官。MidwayBiome是一家私营制药公司，正在开发影响胃肠道和微生物组相互作用的非抗生素方法，以帮助治疗胃肠道和全身疾病。自2016年以来，他一直是Corami LLC的管理合伙人，该公司是一家处于早期阶段的治疗公司，致力于开发将缓释疗法直接输送到心脏外表面的药物设备组合。Pamukcu博士自2019年起担任Syantra，Inc.（一家乳腺癌诊断公司）董事会成员，自2021年起担任Sirpant Immunotherapeutics，Inc.（一家血液系统恶性肿瘤免疫治疗公司）董事会成员，自2018年起担任Virion Therapeutics LLC（一家肝炎治疗疫苗公司）董事会成员。他是国家前列腺癌联盟咨询委员会、美国胃肠病学协会胃肠道肿瘤研究小组、胃肠病学研究小组执行指导委员会和遗传性结肠癌协会科学咨询委员会的成员。自1985年以来，Pamukcu博士在胃肠病学、癌症、癌症化学预防和信号传导系统领域撰写或合著了110多篇期刊文章、书籍章节和摘要。他是150多项已发布或正在申请的专利的发明人，这些专利涉及药物发现和开发用于癌症预防和治疗、炎症性肠病、骨质疏松症以及预防和治疗出血的药物。Pamukcu博士拥有约翰霍普金斯大学生物学学士学位和威斯康星大学医学院医学博士学位。他在Rush Presbyterian St. Luke's Medical Center完成了内科住院治疗，并在芝加哥大学完成了胃肠病学和肝病学研究金。在加入Cell Pathways公司之前，他是辛辛那提大学消化疾病科的助理教授。
- Rifat Pamukcu,has been a member of Board of Aprea Therapeutics, Inc. since May 2022, when he was appointed in connection with Aprea Therapeutics, Inc. acquisition of Atrin Pharmaceuticals, Inc.Dr. Pamukcu has extensive experience in pharmaceuticals and drug development, with a particular focus on oncology.He was a co-founder, director and CSO of Cell Pathways, a publicly traded pharmaceutical company focused on cancer and cancer prevention that was acquired by OSI Pharmaceuticals in 2003). At Cell Pathways he directed the basic science, preclinical drug development, clinical research, regulatory programs, and various aspects of chemical scale-up and manufacturing and raised over $140 million of investment capital. He is currently director, President and CEO of RXMP Therapeutics, Inc. since 2016, a private pharmaceutical company that is developing novel systemically delivered hemostatic agents that are designed to arrest or prevent excessive bleeding. Dr. Pamukcu has served as director, President and CEO of Midway Pharmaceuticals DBA MidwayBiome since 2005, a private pharmaceutical company that is developing nonantibiotic approaches to affect GI tract and microbiome interactions to aid in gastrointestinal and systemic disorders. He has been a Managing Partner of Corami LLC since 2016, an early-stage therapeutics company developing drug-device combinations that deliver sustained release therapeutics directly to the external surface of the heart. Dr. Pamukcu serves on the Board of Directors of Syantra, Inc. since 2019 (a breast cancer diagnostics company), Sirpant Immunotherapeutics, Inc. since 2021 (a hematological malignancy immunotherapeutics company), and Virion Therapeutics LLC since 2018 (a hepatitis therapeutic vaccine company). He has been a member of the Advisory Council to the National Prostate Cancer Coalition, the GI Oncology Task Force of the American Gastroenterological Association, Executive Steering Committee of the Gastroenterology Research Group and Scientific Advisory Board of the Hereditary Colon Cancer Association. Since 1985, Dr. Pamukcu has authored or co-authored over 110 journal articles, book chapters and abstracts in the fields of gastroenterology, cancer, cancer chemoprevention and signal transduction systems. He is an inventor on over 150 issued or pending patents in the areas of drug discovery and development of agents for cancer prevention and therapeutics,inflammatory bowel disease, osteoporosis and the prevention and treatment of hemorrhage. Dr. Pamukcu holds a B.A. in Biology from John Hopkins University and an M.D. from the University of Wisconsin School of Medicine. He completed his Internal Medicine Residency at Rush Presbyterian St. Luke's Medical Center and his Fellowship in Gastroenterology and Hepatology at the University of Chicago. He was an Assistant Professor in the Division of Digestive Diseases at the University of Cincinnati prior to his joining Cell Pathways, Inc.
- Gabriela Gruia
-
Gabriela Gruia，自2023年5月起担任Aprea Therapeutics公司董事会成员。Gruia博士是一位肿瘤学家，在肿瘤药物开发领域拥有超过25年的经验，涵盖细胞和基因治疗、双特异性、生物制剂、免疫治疗和小分子领域，目前担任Gabriela Gruia咨询有限公司的创始人和负责人。从2020年2月到2021年1月，Gruia博士在Ichnos Sciences担任首席开发官，负责多个关键职能的开发活动，包括临床开发和临床运营、监管科学、临床药理学、毒理学和生物统计学。2004年8月至2020年2月，Gruia博士担任诺华肿瘤学高级副总裁兼全球监管事务主管，领导世界级的肿瘤监管事务组织，并与研究合作者、临床前开发、开发组织和高级管理层密切合作，监督所有监管活动。在诺华期间，Gruia博士领导了多个新分子实体的全球提交和批准，包括Tasigna 、Jakavi 、Afinitor 、Signifor 、Zykadia 、Farydak 、Rydapt 、Odomzo 、Kisqali 、Kymriah 、Adakveo 和Piqray 。Gruia博士是TSCAN Therapeutics、Tessa Therapeutics Ltd.和Molecular Templates, Inc.的董事会成员。Gruia博士在罗马尼亚布加勒斯特医学院获得医学博士学位，在法国巴黎的Rene Huguenin/Curie Institute癌症中心获得乳腺病理学和乳腺摄影硕士学位。她在法国巴黎勒内·笛卡尔大学完成了肿瘤学和血液学的培训。
Gabriela Gruia,has been a member of Board of Aprea Therapeutics, Inc. sice May 2023. Dr. Gruia, is an oncologist with over 25 years of experience in oncology drug development, spanning cell and gene therapy, bi-specifics, biologics, immunotherapy, and small molecules and currently serves as the Founder and Principal of Gabriela Gruia Consulting, LLC. From February 2020 to January 2021, Dr. Gruia served as Chief Development Officer at Ichnos Sciences, where she oversaw development activities for several key functions, including Clinical Development and Clinical Operations, Regulatory Sciences, Clinical Pharmacology, Toxicology, and Biostatistics. From August 2004 to February 2020, Dr. Gruia was Senior Vice President and Global Head of Regulatory Affairs for Novartis Oncology, where she led the world class oncology regulatory affairs organization and oversaw all regulatory activities in close partnership with research collaborators, preclinical development, development organization and senior management. While at Novartis, Dr. Gruia spearheaded the worldwide submission and approval of multiple new molecular entities, including Tasigna, Jakavi, Afinitor, Signifor, Zykadia, Farydak, Rydapt, Odomzo, Kisqali, Kymriah, Adakveo, and Piqray. Dr. Gruia serves as a member of the board of directors of TSCAN Therapeutics, Tessa Therapeutics Ltd., and Molecular Templates, Inc. Dr. Gruia earned a doctorate in medicine from Bucharest Medical School in Romania and a Masters in Breast Pathology and Mammography from the Rene Huguenin/Curie Institute Cancer Center in Paris, France. She completed training in oncology and hematology at Rene Descartes University in Paris, France. - Gabriela Gruia，自2023年5月起担任Aprea Therapeutics公司董事会成员。Gruia博士是一位肿瘤学家，在肿瘤药物开发领域拥有超过25年的经验，涵盖细胞和基因治疗、双特异性、生物制剂、免疫治疗和小分子领域，目前担任Gabriela Gruia咨询有限公司的创始人和负责人。从2020年2月到2021年1月，Gruia博士在Ichnos Sciences担任首席开发官，负责多个关键职能的开发活动，包括临床开发和临床运营、监管科学、临床药理学、毒理学和生物统计学。2004年8月至2020年2月，Gruia博士担任诺华肿瘤学高级副总裁兼全球监管事务主管，领导世界级的肿瘤监管事务组织，并与研究合作者、临床前开发、开发组织和高级管理层密切合作，监督所有监管活动。在诺华期间，Gruia博士领导了多个新分子实体的全球提交和批准，包括Tasigna 、Jakavi 、Afinitor 、Signifor 、Zykadia 、Farydak 、Rydapt 、Odomzo 、Kisqali 、Kymriah 、Adakveo 和Piqray 。Gruia博士是TSCAN Therapeutics、Tessa Therapeutics Ltd.和Molecular Templates, Inc.的董事会成员。Gruia博士在罗马尼亚布加勒斯特医学院获得医学博士学位，在法国巴黎的Rene Huguenin/Curie Institute癌症中心获得乳腺病理学和乳腺摄影硕士学位。她在法国巴黎勒内·笛卡尔大学完成了肿瘤学和血液学的培训。
- Gabriela Gruia,has been a member of Board of Aprea Therapeutics, Inc. sice May 2023. Dr. Gruia, is an oncologist with over 25 years of experience in oncology drug development, spanning cell and gene therapy, bi-specifics, biologics, immunotherapy, and small molecules and currently serves as the Founder and Principal of Gabriela Gruia Consulting, LLC. From February 2020 to January 2021, Dr. Gruia served as Chief Development Officer at Ichnos Sciences, where she oversaw development activities for several key functions, including Clinical Development and Clinical Operations, Regulatory Sciences, Clinical Pharmacology, Toxicology, and Biostatistics. From August 2004 to February 2020, Dr. Gruia was Senior Vice President and Global Head of Regulatory Affairs for Novartis Oncology, where she led the world class oncology regulatory affairs organization and oversaw all regulatory activities in close partnership with research collaborators, preclinical development, development organization and senior management. While at Novartis, Dr. Gruia spearheaded the worldwide submission and approval of multiple new molecular entities, including Tasigna, Jakavi, Afinitor, Signifor, Zykadia, Farydak, Rydapt, Odomzo, Kisqali, Kymriah, Adakveo, and Piqray. Dr. Gruia serves as a member of the board of directors of TSCAN Therapeutics, Tessa Therapeutics Ltd., and Molecular Templates, Inc. Dr. Gruia earned a doctorate in medicine from Bucharest Medical School in Romania and a Masters in Breast Pathology and Mammography from the Rene Huguenin/Curie Institute Cancer Center in Paris, France. She completed training in oncology and hematology at Rene Descartes University in Paris, France.
- Oren Gilad
-
Oren Gilad，自2022年7月起担任Aprea Therapeutics公司首席执行官。他自2022年5月起担任Aprea Therapeutics公司总裁和董事会成员，当时他因Aprea Therapeutics公司收购私人持有的肿瘤发现公司Atrin Pharmaceuticals，Inc.而被任命。Gilad博士拥有二十多年的学术、私人和公共生物技术行业经验，并在药物开发的各个阶段拥有广泛的领导经验。在2011年至2022年加入Aprea之前，他是Atrin Pharmaceuticals，Inc.的首席执行官。在创立Atrin Pharmaceuticals之前。在2011年，吉拉德博士有13年的学术生涯，在那里他撰写了许多高影响力的科学文章，其中一篇文章证明了ATR通路在癌症发展和预防中的重要性。这项突破性研究是在宾夕法尼亚大学进行的。吉拉德博士拥有希伯来大学的学士学位、加州大学戴维斯分校的博士和博士后学位，以及宾夕法尼亚大学的博士后学位。
Oren Gilad,has served as Chief Executive Officer of Aprea Therapeutics, Inc. since July 2022. He has serves as President and a member of Board of Aprea Therapeutics, Inc. since May 2022, when he was appointed in connection with Aprea Therapeutics, Inc. acquisition of Atrin Pharmaceuticals, Inc., a privately held oncology discovery company. Dr. Gilad has more than twenty years of academic, private and public biotechnology industry experience, as well as extensive leadership experience across all phases of drug development. Prior to joining Aprea, from 2011 to 2022, he was the Chief Executive Officer of Atrin Pharmaceuticals, Inc. Prior to founding Atrin Pharmaceuticals. Inc. in 2011, Dr. Gilad had a 13-year academic career, where he authored numerous high impact scientific articles, including one that demonstrated the importance of the ATR pathway in cancer development and prevention. This breakthrough research was conducted at the University of Pennsylvania. Dr. Gilad holds a B.Sc from the Hebrew University, a Ph.D. and post-doctorate from the University of California at Davis, and a post-doctorate from the University of Pennsylvania. - Oren Gilad，自2022年7月起担任Aprea Therapeutics公司首席执行官。他自2022年5月起担任Aprea Therapeutics公司总裁和董事会成员，当时他因Aprea Therapeutics公司收购私人持有的肿瘤发现公司Atrin Pharmaceuticals，Inc.而被任命。Gilad博士拥有二十多年的学术、私人和公共生物技术行业经验，并在药物开发的各个阶段拥有广泛的领导经验。在2011年至2022年加入Aprea之前，他是Atrin Pharmaceuticals，Inc.的首席执行官。在创立Atrin Pharmaceuticals之前。在2011年，吉拉德博士有13年的学术生涯，在那里他撰写了许多高影响力的科学文章，其中一篇文章证明了ATR通路在癌症发展和预防中的重要性。这项突破性研究是在宾夕法尼亚大学进行的。吉拉德博士拥有希伯来大学的学士学位、加州大学戴维斯分校的博士和博士后学位，以及宾夕法尼亚大学的博士后学位。
- Oren Gilad,has served as Chief Executive Officer of Aprea Therapeutics, Inc. since July 2022. He has serves as President and a member of Board of Aprea Therapeutics, Inc. since May 2022, when he was appointed in connection with Aprea Therapeutics, Inc. acquisition of Atrin Pharmaceuticals, Inc., a privately held oncology discovery company. Dr. Gilad has more than twenty years of academic, private and public biotechnology industry experience, as well as extensive leadership experience across all phases of drug development. Prior to joining Aprea, from 2011 to 2022, he was the Chief Executive Officer of Atrin Pharmaceuticals, Inc. Prior to founding Atrin Pharmaceuticals. Inc. in 2011, Dr. Gilad had a 13-year academic career, where he authored numerous high impact scientific articles, including one that demonstrated the importance of the ATR pathway in cancer development and prevention. This breakthrough research was conducted at the University of Pennsylvania. Dr. Gilad holds a B.Sc from the Hebrew University, a Ph.D. and post-doctorate from the University of California at Davis, and a post-doctorate from the University of Pennsylvania.
- Christian S. Schade
-
Christian S. Schade，自2006年起任公司董事。目前，他是Novira Therapeutics的首席执行官，该公司是一家抗病毒延误发现公司，专注于慢性乙型肝炎的首创治疗。 在2004年3月加入Novira Therapeutics之前，他从2011年9月至2013年7月担任Omthera Pharmaceuticals, Inc. 的首席执行官和执行副总裁，该公司是一家新兴特殊制公司，专注于血脂障碍的临床疗法，直到2013年7月被AstraZeneca 购买。2010年4月至2011年9月，他担任From April 2010 to September 2011 Mr. NRG Energy的执行副总裁兼首席财务官，在此他负责企业财务运作，包括财政、会计、税收、风险、信贷管理和保险。在加入NRG之前，他是Medarex Inc.的行政高级副总裁兼首席财务官，该公司是一级纳克达斯上市的位于普林斯顿的生物只要公司。他协助Medarex成长为一家领先的制药开发公司，通过一系列公共资本市场和资产货币化交易从而融资。在此，他也监管多种发展和临床项目，且负责业务发展团队。 在2000年加入Medarex之前，他在伦敦Merrill Lynch担任董事总经理，在此他是欧洲企业融资租负责人，负责资本市场活动。他哎纽约和伦敦的Merrill Lynch和 JP Morgan Chase & Co.也担任许多企业财务和资本市场职务。他目前担任Princeton Academy School董事会主席。他持有普林斯顿大学（Princeton University）文学士学位，宾夕法尼亚大学沃顿商学院（ the Wharton School at the University of Pennsylvania）工商管理硕士学位。
Christian S. Schade,has served as a member of Board of Aprea Therapeutics, Inc. since June 2016 and currently acts as Chairman. From June 2016 until July 2022, he was President and Chief Executive Officer of Aprea Therapeutics, Inc. and concurrent with the completion of the acquisition of Atrin Pharmaceuticals, Inc. served as Executive Chairman of the Board until January 2023. Mr. Schade has more than 30 years of private and public pharmaceutical and biotechnology industry experience, as well as broad corporate finance expertise from his tenure in investment banking. Mr. Schade currently serves as Growth Partner at Flagship Pioneering. Prior to joining Aprea, from 2014 to 2015, he was Chief Executive Officer of Novira, a privately held antiviral drug discovery company until it was acquired by Johnson & Johnson. Prior to joining Novira, Mr. Schade was Executive Vice President and Chief Financial Officer of Omthera Pharmaceuticals, Inc. ("Omthera"), a Nasdaq-listed specialty pharmaceuticals company focused on the development and commercialization of new therapies for dyslipidemia until it was acquired by AstraZeneca Plc. He also was Executive Vice President and Chief Financial Officer at NYSE-listed NRG Energy Inc., and from 2000 to 2009, he was Senior Vice President of Administration and Chief Financial Officer at Medarex, Inc. ("Medarex"), a biopharmaceutical company focused on antibody-based therapeutic products for oncology, inflammation, autoimmune disorders, and infectious diseases until it was acquired by Bristol-Myers Squibb Company. Before joining Medarex, Mr. Schade served as Managing Director at Merrill Lynch in London and held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Mr. Schade currently serves on the board of directors of Sapience Therapeutics, Inc., and Integra LifeSciences Holdings Corporation, where he chairs the Finance Committee. Mr. Schade received an M.B.A. from the Wharton School at the University of Pennsylvania and an A.B. from Princeton University. - Christian S. Schade，自2006年起任公司董事。目前，他是Novira Therapeutics的首席执行官，该公司是一家抗病毒延误发现公司，专注于慢性乙型肝炎的首创治疗。 在2004年3月加入Novira Therapeutics之前，他从2011年9月至2013年7月担任Omthera Pharmaceuticals, Inc. 的首席执行官和执行副总裁，该公司是一家新兴特殊制公司，专注于血脂障碍的临床疗法，直到2013年7月被AstraZeneca 购买。2010年4月至2011年9月，他担任From April 2010 to September 2011 Mr. NRG Energy的执行副总裁兼首席财务官，在此他负责企业财务运作，包括财政、会计、税收、风险、信贷管理和保险。在加入NRG之前，他是Medarex Inc.的行政高级副总裁兼首席财务官，该公司是一级纳克达斯上市的位于普林斯顿的生物只要公司。他协助Medarex成长为一家领先的制药开发公司，通过一系列公共资本市场和资产货币化交易从而融资。在此，他也监管多种发展和临床项目，且负责业务发展团队。 在2000年加入Medarex之前，他在伦敦Merrill Lynch担任董事总经理，在此他是欧洲企业融资租负责人，负责资本市场活动。他哎纽约和伦敦的Merrill Lynch和 JP Morgan Chase & Co.也担任许多企业财务和资本市场职务。他目前担任Princeton Academy School董事会主席。他持有普林斯顿大学（Princeton University）文学士学位，宾夕法尼亚大学沃顿商学院（ the Wharton School at the University of Pennsylvania）工商管理硕士学位。
- Christian S. Schade,has served as a member of Board of Aprea Therapeutics, Inc. since June 2016 and currently acts as Chairman. From June 2016 until July 2022, he was President and Chief Executive Officer of Aprea Therapeutics, Inc. and concurrent with the completion of the acquisition of Atrin Pharmaceuticals, Inc. served as Executive Chairman of the Board until January 2023. Mr. Schade has more than 30 years of private and public pharmaceutical and biotechnology industry experience, as well as broad corporate finance expertise from his tenure in investment banking. Mr. Schade currently serves as Growth Partner at Flagship Pioneering. Prior to joining Aprea, from 2014 to 2015, he was Chief Executive Officer of Novira, a privately held antiviral drug discovery company until it was acquired by Johnson & Johnson. Prior to joining Novira, Mr. Schade was Executive Vice President and Chief Financial Officer of Omthera Pharmaceuticals, Inc. ("Omthera"), a Nasdaq-listed specialty pharmaceuticals company focused on the development and commercialization of new therapies for dyslipidemia until it was acquired by AstraZeneca Plc. He also was Executive Vice President and Chief Financial Officer at NYSE-listed NRG Energy Inc., and from 2000 to 2009, he was Senior Vice President of Administration and Chief Financial Officer at Medarex, Inc. ("Medarex"), a biopharmaceutical company focused on antibody-based therapeutic products for oncology, inflammation, autoimmune disorders, and infectious diseases until it was acquired by Bristol-Myers Squibb Company. Before joining Medarex, Mr. Schade served as Managing Director at Merrill Lynch in London and held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Mr. Schade currently serves on the board of directors of Sapience Therapeutics, Inc., and Integra LifeSciences Holdings Corporation, where he chairs the Finance Committee. Mr. Schade received an M.B.A. from the Wharton School at the University of Pennsylvania and an A.B. from Princeton University.
- John B. Henneman, III
-
John B. Henneman, III，自2019年8月起担任Aprea Therapeutics, Inc.的董事会成员。从2018年7月至2018年11月，Henneman先生担任生物技术公司NewLink Genetics Corporation（“NewLink”）的首席行政官。2014年10月至2018年7月，Henneman先生担任NewLink的执行副总裁兼首席财务官。从1998年到2014年，Henneman先生担任Integra LifeSciences Holdings Corporation（“Integra”）（一家上市的医疗设备公司）的各种职务。在2007年成为Integra的首席财务官之前，Henneman先生是首席行政官，负责Integra的法规事务、质量体系、临床事务、人力资源、信息系统和法律事务职能、Integra手术器械业务的管理以及Integra的业务发展职能。他目前担任R1 RCM公司（一家公开持有的收入周期技术和管理服务公司）、Orthofix Medical公司（一家公开持有的医疗技术公司）、Anika Therapeutics公司（一家公开持有的医疗技术公司）和Alafair Biosciences公司（一家私人持有的医疗设备公司）的董事会成员。他也是Prettybrook Partners（私募股权公司）的高级顾问，以及SparkMed Advisors LLC（为初创医疗设备和生物技术公司提供咨询和其他服务）的顾问。
John B. Henneman, III,has been a member of Board of Aprea Therapeutics, Inc. since August 2019. From July 2018 until November 2018, Mr. Henneman served as the Chief Administrative Officer of NewLink Genetics Corporation ("NewLink"), a biotechnology company. From October 2014 to July 2018, Mr. Henneman served as NewLink's Executive Vice President and Chief Financial Officer. From 1998 to 2014, Mr. Henneman served at Integra LifeSciences Holdings Corporation ("Integra"), a publicly-held medical device company, in various capacities. Before becoming Integra's Chief Financial Officer in 2007, Mr. Henneman was Chief Administrative Officer, responsible for Integra's regulatory affairs, quality systems, clinical affairs, human resources, information systems and legal affairs functions, the management of Integra's surgical instruments business, and Integra's business development function. Mr. Henneman currently serves on the boards of directors of R1 RCM Inc., a publicly-held revenue cycle technology and management services company, Orthofix Medical, Inc., a publicly-held medical technology company, Anika Therapeutics, Inc., a publicly held medical technology company and Alafair Biosciences, Inc., a privately-held medical device company. Mr. Henneman is also senior advisor to Prettybrook Partners, a private equity firm, and a consultant with SparkMed Advisors LLC, which provides consulting and other services to start-up medical device and biotechnology companies. - John B. Henneman, III，自2019年8月起担任Aprea Therapeutics, Inc.的董事会成员。从2018年7月至2018年11月，Henneman先生担任生物技术公司NewLink Genetics Corporation（“NewLink”）的首席行政官。2014年10月至2018年7月，Henneman先生担任NewLink的执行副总裁兼首席财务官。从1998年到2014年，Henneman先生担任Integra LifeSciences Holdings Corporation（“Integra”）（一家上市的医疗设备公司）的各种职务。在2007年成为Integra的首席财务官之前，Henneman先生是首席行政官，负责Integra的法规事务、质量体系、临床事务、人力资源、信息系统和法律事务职能、Integra手术器械业务的管理以及Integra的业务发展职能。他目前担任R1 RCM公司（一家公开持有的收入周期技术和管理服务公司）、Orthofix Medical公司（一家公开持有的医疗技术公司）、Anika Therapeutics公司（一家公开持有的医疗技术公司）和Alafair Biosciences公司（一家私人持有的医疗设备公司）的董事会成员。他也是Prettybrook Partners（私募股权公司）的高级顾问，以及SparkMed Advisors LLC（为初创医疗设备和生物技术公司提供咨询和其他服务）的顾问。
- John B. Henneman, III,has been a member of Board of Aprea Therapeutics, Inc. since August 2019. From July 2018 until November 2018, Mr. Henneman served as the Chief Administrative Officer of NewLink Genetics Corporation ("NewLink"), a biotechnology company. From October 2014 to July 2018, Mr. Henneman served as NewLink's Executive Vice President and Chief Financial Officer. From 1998 to 2014, Mr. Henneman served at Integra LifeSciences Holdings Corporation ("Integra"), a publicly-held medical device company, in various capacities. Before becoming Integra's Chief Financial Officer in 2007, Mr. Henneman was Chief Administrative Officer, responsible for Integra's regulatory affairs, quality systems, clinical affairs, human resources, information systems and legal affairs functions, the management of Integra's surgical instruments business, and Integra's business development function. Mr. Henneman currently serves on the boards of directors of R1 RCM Inc., a publicly-held revenue cycle technology and management services company, Orthofix Medical, Inc., a publicly-held medical technology company, Anika Therapeutics, Inc., a publicly held medical technology company and Alafair Biosciences, Inc., a privately-held medical device company. Mr. Henneman is also senior advisor to Prettybrook Partners, a private equity firm, and a consultant with SparkMed Advisors LLC, which provides consulting and other services to start-up medical device and biotechnology companies.
高管简历
中英对照 | 中文 | 英文- Oren Gilad
Oren Gilad，自2022年7月起担任Aprea Therapeutics公司首席执行官。他自2022年5月起担任Aprea Therapeutics公司总裁和董事会成员，当时他因Aprea Therapeutics公司收购私人持有的肿瘤发现公司Atrin Pharmaceuticals，Inc.而被任命。Gilad博士拥有二十多年的学术、私人和公共生物技术行业经验，并在药物开发的各个阶段拥有广泛的领导经验。在2011年至2022年加入Aprea之前，他是Atrin Pharmaceuticals，Inc.的首席执行官。在创立Atrin Pharmaceuticals之前。在2011年，吉拉德博士有13年的学术生涯，在那里他撰写了许多高影响力的科学文章，其中一篇文章证明了ATR通路在癌症发展和预防中的重要性。这项突破性研究是在宾夕法尼亚大学进行的。吉拉德博士拥有希伯来大学的学士学位、加州大学戴维斯分校的博士和博士后学位，以及宾夕法尼亚大学的博士后学位。
Oren Gilad,has served as Chief Executive Officer of Aprea Therapeutics, Inc. since July 2022. He has serves as President and a member of Board of Aprea Therapeutics, Inc. since May 2022, when he was appointed in connection with Aprea Therapeutics, Inc. acquisition of Atrin Pharmaceuticals, Inc., a privately held oncology discovery company. Dr. Gilad has more than twenty years of academic, private and public biotechnology industry experience, as well as extensive leadership experience across all phases of drug development. Prior to joining Aprea, from 2011 to 2022, he was the Chief Executive Officer of Atrin Pharmaceuticals, Inc. Prior to founding Atrin Pharmaceuticals. Inc. in 2011, Dr. Gilad had a 13-year academic career, where he authored numerous high impact scientific articles, including one that demonstrated the importance of the ATR pathway in cancer development and prevention. This breakthrough research was conducted at the University of Pennsylvania. Dr. Gilad holds a B.Sc from the Hebrew University, a Ph.D. and post-doctorate from the University of California at Davis, and a post-doctorate from the University of Pennsylvania.- Oren Gilad，自2022年7月起担任Aprea Therapeutics公司首席执行官。他自2022年5月起担任Aprea Therapeutics公司总裁和董事会成员，当时他因Aprea Therapeutics公司收购私人持有的肿瘤发现公司Atrin Pharmaceuticals，Inc.而被任命。Gilad博士拥有二十多年的学术、私人和公共生物技术行业经验，并在药物开发的各个阶段拥有广泛的领导经验。在2011年至2022年加入Aprea之前，他是Atrin Pharmaceuticals，Inc.的首席执行官。在创立Atrin Pharmaceuticals之前。在2011年，吉拉德博士有13年的学术生涯，在那里他撰写了许多高影响力的科学文章，其中一篇文章证明了ATR通路在癌症发展和预防中的重要性。这项突破性研究是在宾夕法尼亚大学进行的。吉拉德博士拥有希伯来大学的学士学位、加州大学戴维斯分校的博士和博士后学位，以及宾夕法尼亚大学的博士后学位。
- Oren Gilad,has served as Chief Executive Officer of Aprea Therapeutics, Inc. since July 2022. He has serves as President and a member of Board of Aprea Therapeutics, Inc. since May 2022, when he was appointed in connection with Aprea Therapeutics, Inc. acquisition of Atrin Pharmaceuticals, Inc., a privately held oncology discovery company. Dr. Gilad has more than twenty years of academic, private and public biotechnology industry experience, as well as extensive leadership experience across all phases of drug development. Prior to joining Aprea, from 2011 to 2022, he was the Chief Executive Officer of Atrin Pharmaceuticals, Inc. Prior to founding Atrin Pharmaceuticals. Inc. in 2011, Dr. Gilad had a 13-year academic career, where he authored numerous high impact scientific articles, including one that demonstrated the importance of the ATR pathway in cancer development and prevention. This breakthrough research was conducted at the University of Pennsylvania. Dr. Gilad holds a B.Sc from the Hebrew University, a Ph.D. and post-doctorate from the University of California at Davis, and a post-doctorate from the University of Pennsylvania.
- John P. Hamill
John P. Hamill，自2023年1月起担任Aprea Therapeutics公司高级副总裁、首席财务官和秘书。从2020年6月至2023年1月，Hamill先生担任Windtree Therapeutics, Inc.的高级副总裁兼首席财务官，该公司是一家生物制药公司，专注于开发新疗法，旨在满足重要急症护理市场中大量未满足的医疗需求。从2019年9月至2020年6月，Hamill先生保持了提供财务和首席财务官服务的咨询业务。2018年8月至2019年8月，他担任Trevena, Inc.的财务副总裁兼首席财务官，该公司是一家专注于中枢神经系统疾病患者新药开发和商业化的生物制药公司。从2017年6月到2018年7月，哈米尔一直从事咨询业务，提供首席财务官服务，比如筹集资金和编制预算。从2014年1月至2016年3月，哈米尔先生担任NephroGenex公司的首席财务官，从2016年4月至2017年5月，哈米尔先生获得了DeSales大学会计学/商业和计算机科学双专业的学士学位。Hamill先生是一名注册会计师，是宾夕法尼亚注册会计师协会和美国注册会计师协会的成员。
John P. Hamill,has served as Senior Vice President, Chief Financial Officer and Secretary of Aprea Therapeutics, Inc. since January 2023. From June 2020 to January 2023, Mr. Hamill served as Senior Vice President and Chief Financial Officer of Windtree Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Mr. Hamill maintained a consulting practice offering financial and chief financial officer services from September 2019 to June 2020. From August 2018 to August 2019, he served as the Vice President of Finance and Chief Financial Officer of Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders. From June 2017 through July 2018, Mr. Hamill maintained a consulting practice offering chief financial officer services such as, amongst other things, raising capital and budgeting. From January 2014 through March 2016, Mr. Hamill was Chief Financial Officer and from April 2016 through May 2017 Chief Executive Officer and Chief Financial Officer for NephroGenex, Inc. Mr. Hamill earned his B.S. with a dual major in Accounting/Business and Computer Science from DeSales University. Mr. Hamill is a Certified Public Accountant and is a member of the Pennsylvania Institute of Certified Public Accountants and the American Institute of Certified Public Accountants.- John P. Hamill，自2023年1月起担任Aprea Therapeutics公司高级副总裁、首席财务官和秘书。从2020年6月至2023年1月，Hamill先生担任Windtree Therapeutics, Inc.的高级副总裁兼首席财务官，该公司是一家生物制药公司，专注于开发新疗法，旨在满足重要急症护理市场中大量未满足的医疗需求。从2019年9月至2020年6月，Hamill先生保持了提供财务和首席财务官服务的咨询业务。2018年8月至2019年8月，他担任Trevena, Inc.的财务副总裁兼首席财务官，该公司是一家专注于中枢神经系统疾病患者新药开发和商业化的生物制药公司。从2017年6月到2018年7月，哈米尔一直从事咨询业务，提供首席财务官服务，比如筹集资金和编制预算。从2014年1月至2016年3月，哈米尔先生担任NephroGenex公司的首席财务官，从2016年4月至2017年5月，哈米尔先生获得了DeSales大学会计学/商业和计算机科学双专业的学士学位。Hamill先生是一名注册会计师，是宾夕法尼亚注册会计师协会和美国注册会计师协会的成员。
- John P. Hamill,has served as Senior Vice President, Chief Financial Officer and Secretary of Aprea Therapeutics, Inc. since January 2023. From June 2020 to January 2023, Mr. Hamill served as Senior Vice President and Chief Financial Officer of Windtree Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Mr. Hamill maintained a consulting practice offering financial and chief financial officer services from September 2019 to June 2020. From August 2018 to August 2019, he served as the Vice President of Finance and Chief Financial Officer of Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders. From June 2017 through July 2018, Mr. Hamill maintained a consulting practice offering chief financial officer services such as, amongst other things, raising capital and budgeting. From January 2014 through March 2016, Mr. Hamill was Chief Financial Officer and from April 2016 through May 2017 Chief Executive Officer and Chief Financial Officer for NephroGenex, Inc. Mr. Hamill earned his B.S. with a dual major in Accounting/Business and Computer Science from DeSales University. Mr. Hamill is a Certified Public Accountant and is a member of the Pennsylvania Institute of Certified Public Accountants and the American Institute of Certified Public Accountants.